Literature DB >> 23365083

Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis.

Krista G Haanstra1, Sam O Hofman, Dave M Lopes Estêvão, Erwin L A Blezer, Jan Bauer, Li-Li Yang, Tim Wyant, Vilmos Csizmadia, Bert A 't Hart, Eric R Fedyk.   

Abstract

The immune system is characterized by the preferential migration of lymphocytes through specific tissues (i.e., tissue tropism). Tissue tropism is mediated, in part, by the α(4) integrins expressed by T lymphocytes. The α(4)β(1) integrin mediates migration of memory T lymphocytes into the CNS, whereas the α(4)β(7) integrin mediates migration preferentially into gastrointestinal tissue. This paradigm was established primarily from investigations in rodents; thus, the objective of this investigation was to determine if blocking the α(4)β(7) integrin exclusively would affect migration of T lymphocytes into the CNS of primates. The effects of the dual α(4)β(1) and α(4)β(7) antagonist natalizumab were compared with those of the α(4)β(7) antagonist vedolizumab on experimental autoimmune encephalomyelitis in the rhesus monkey. Animals received an initial i.v. bolus of placebo, natalizumab (30 mg/kg), or vedolizumab (30 mg/kg) before intracutaneous immunization with recombinant human myelin oligodendrocyte glycoprotein and then Ab once weekly thereafter. Natalizumab prevented CNS inflammation and demyelination significantly (p < 0.05), compared with time-matched placebo control animals, whereas vedolizumab did not inhibit these effects, despite saturating the α(4)β(7) integrin in each animal for the duration of the investigation. These results demonstrate that blocking α(4)β(7) exclusively does not inhibit immune surveillance of the CNS in primates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365083     DOI: 10.4049/jimmunol.1202490

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

Review 3.  A product review of vedolizumab in inflammatory bowel disease.

Authors:  Robert Battat; Parambir S Dulai; Vipul Jairath; Niels Vande Casteele
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

Review 4.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

Review 5.  Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.

Authors:  Yu Jin; Yan Lin; Lian-Jie Lin; Chang-Qing Zheng
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 6.  Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.

Authors:  Robert Battat; Christopher Ma; Vipul Jairath; Reena Khanna; Brian G Feagan
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 7.  Biological therapy for ulcerative colitis: an update.

Authors:  Geom Seog Seo; Soo-Cheon Chae
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

8.  First integrin inhibitor since Tysabri nears approval for IBD.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-03       Impact factor: 54.908

Review 9.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

Review 10.  Inflammatory pathways of importance for management of inflammatory bowel disease.

Authors:  Jannie Pedersen; Mehmet Coskun; Christoffer Soendergaard; Mohammad Salem; Ole Haagen Nielsen
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.